Study of BMS-986158 in Subjects With Select Advanced Cancers
Trial Status: Closed to Accrual
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
Inclusion Criteria
- Must have select advanced cancers with specific genetic profiles
- Must have received appropriate standard of care
- At least one measurable lesion at baseline
- Expected to have life expectancy of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) of 0 to 1
Exclusion Criteria
- Concomitant second malignancies
- Uncontrolled or significant cardiovascular disease
- Inadequate bone marrow function
- Chronic gastrointestinal illness
- Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor
California
Duarte
City of Hope Comprehensive Cancer Center
Status: ACTIVE
Contact: Mihaela C. Cristea
Phone: 626-359-8111
Email:
becomingapatient@coh.org
Colorado
Aurora
University of Colorado Hospital
Status: CLOSED_TO_ACCRUAL
Massachusetts
Boston
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE
Missouri
Saint Louis
Siteman Cancer Center at Washington University
Status: WITHDRAWN
Oregon
Portland
OHSU Knight Cancer Institute
Status: CLOSED_TO_ACCRUAL
Pennsylvania
Philadelphia
University of Pennsylvania / Abramson Cancer Center
Status: ACTIVE
Trial Phase Phase I/II
Trial Type Treatment
Lead Organization
Bristol-Myers Squibb
- Primary ID CA011-001
- Secondary IDs NCI-2016-01458, 2015-000324-29
- Clinicaltrials.gov ID NCT02419417